# iBio, Inc.

iBio, Inc. is a public company listed on Nasdaq as IBIO, headquartered in New York, NY, United States.

## Company overview

- **Legal name:** iBio, Inc.
- **Former names in filing history:** iBio, Inc. (2009-08-18 to 2026-10-13); iBioPharma, Inc. (2008-07-16 to 2009-08-14); InB:Biotechnologies, Inc. (2008-03-07 to 2008-07-17)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** New York, NY, United States
- **Incorporated in:** DE
- **Fiscal year end:** June 30
- **Ticker:** Nasdaq: IBIO
- **SEC CIK:** 0001420720

## About

iBio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001420720, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-08-28, it reported annual revenue of USD 100,000; net income of USD -33,044,000; total assets of USD 99,110,000 for the fiscal period ended 2026-06-30. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2026 (period ended 2026-06-30)

- **Revenue:** $100,000 (USD 100,000)
- **Net income:** -$33.0M (USD -33,044,000)
- **Total assets:** $99.1M (USD 99,110,000)
- **Cash and equivalents:** $56.4M (USD 56,395,000)
- **Operating cash flow:** -$23.2M (USD -23,218,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2025 (period ended 2025-06-30)

- **Revenue:** $400,000 (USD 400,000)
- **Net income:** -$18.4M (USD -18,377,000)
- **Total assets:** $23.2M (USD 23,185,000)
- **Cash and equivalents:** $8.6M (USD 8,582,000)
- **Operating cash flow:** -$15.3M (USD -15,304,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-06-30)

- **Revenue:** $225,000 (USD 225,000)
- **Net income:** -$24.9M (USD -24,907,000)
- **Total assets:** $28.7M (USD 28,734,000)
- **Cash and equivalents:** $14.2M (USD 14,210,000)
- **Operating cash flow:** -$18.6M (USD -18,554,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2023 (period ended 2023-06-30)

- **Revenue:** $0 (USD 0)
- **Total assets:** $41.2M (USD 41,207,000)
- **Cash and equivalents:** $4.3M (USD 4,301,000)
- **Operating cash flow:** -$30.4M (USD -30,436,000)

## Recent SEC filings

- Form 8-K — filed 2026-10-13 — period 2026-10-13 — 8-K
- Form 8-K — filed 2026-09-14 — period 2026-09-14 — 8-K
- Form DEF 14A — filed 2026-09-04 — period 2026-09-04 — DEF 14A
- Form 10-K — filed 2026-08-28 — period 2026-06-30 — 10-K
- Form 8-K — filed 2026-08-28 — period 2026-08-28 — 8-K
- Form 8-K — filed 2026-08-04 — period 2026-07-31 — 8-K
- Form 8-K — filed 2026-07-17 — period 2026-07-17 — 8-K
- Form 8-K — filed 2026-07-01 — period 2026-07-01 — 8-K
- Form 10-Q — filed 2026-05-12 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-12 — period 2026-05-12 — 8-K
- Form 8-K — filed 2026-05-08 — period 2026-05-07 — 8-K
- Form 8-K — filed 2026-04-08 — period 2026-04-08 — 8-K

---

Updated: 2026-10-23T06:09:42Z

Canonical page: https://altss.com/profile/ibio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology